A citation-based method for searching scientific literature

Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
Times Cited: 502



Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Faiez Zannad. JAMA Cardiol 2017
Times Cited: 174




List of shared articles



Times cited

Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal. Adv Exp Med Biol 2021
4




Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes.
Nick S R Lan, Bu B Yeap, P Gerry Fegan, Gillian Green, James M Rankin, Girish Dwivedi. Int J Cardiovasc Imaging 2021
2

Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Rumyana Dimova, Tsvetalina Tankova. Horm Metab Res 2021
0

The role of sodium glucose co-transporter inhibitors in heart failure prevention.
Vishnu Garla, Angela Subauste, Javed Butler, Lillian F Lien. J Diabetes Complications 2021
0


Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis.
Kai Jiang, Yue Xu, Dandan Wang, Feng Chen, Zizhuo Tu, Jie Qian, Sheng Xu, Yixiang Xu, John Hwa, Jian Li,[...]. Protein Cell 2021
5

Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review.
Vincenzo Mollace, Giuseppe M C Rosano, Stefan D Anker, Andrew J S Coats, Petar Seferovic, Rocco Mollace, Annamaria Tavernese, Micaela Gliozzi, Vincenzo Musolino, Cristina Carresi,[...]. Nutrients 2021
3

Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial.
Jawad H Butt, Jose C Nicolau, Subodh Verma, Kieran F Docherty, Mark C Petrie, Silvio E Inzucchi, Morten Schou, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez,[...]. Eur J Heart Fail 2021
6

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.
Qingchun Zeng, Qing Zhou, Weitao Liu, Yutong Wang, Xingbo Xu, Dingli Xu. Front Cardiovasc Med 2021
2

Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
Jawad H Butt, Kieran F Docherty, Mark C Petrie, Morten Schou, Mikhail N Kosiborod, Eileen O'Meara, Tzvetana Katova, Charlotta E A Ljungman, Mirta Diez, Modele O Ogunniyi,[...]. JAMA Cardiol 2021
3


SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives.
Vishnu Vardhan Garla, Javed Butler, Lillian F Lien. Curr Cardiol Rep 2021
0

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Hang-Long Li, Gregory Y H Lip, Qi Feng, Yue Fei, Yi-Kei Tse, Mei-Zhen Wu, Qing-Wen Ren, Hung-Fat Tse, Bernard-M Y Cheung, Kai-Hang Yiu. Cardiovasc Diabetol 2021
8

Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction.
Ammar G Chaudhary, Fadi M Alreefi, Mohammad A Aziz. CJC Open 2021
0

Towards precision medicine in heart failure.
Chad S Weldy, Euan A Ashley. Nat Rev Cardiol 2021
0